Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07345494
A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
Sponsor: Ascendis Pharma A/S
View on ClinicalTrials.gov
Summary
The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.
Key Details
Gender
FEMALE
Age Range
15 Years - 50 Years
Study Type
OBSERVATIONAL
Enrollment
50
Start Date
2026-02-18
Completion Date
2036-01
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
Palopegteriparatide
Palopegteriparatide prescribed as per normal clinical practice
Locations (1)
Ascendis Investigational Site
Morgantown, West Virginia, United States